Translation
Original language
14.05.2026
From OSCAR to BODY-OS: From a Closed System to Open-Source Code. Module Bioplatform as a Driver of a New Economy and Longevity
INTRODUCTION
Cornelis Vlasman’s OSCAR project is hypothetical in nature, yet it is a powerful conceptual model that points to the coming technological watershed. Its central idea of transitioning from perceiving the body as a “closed system” to a “modular, open architecture” is key both to a revolution in medicine, and to shaping radically new high-tech markets and sustainable economic growth models based on the value of human life and health.
Relevance
Today, the global economy faces two challenges at once: aging population in developed countries and increasing incidence of chronic diseases, which results in massive healthcare spending. Simultaneously, there is a crisis of organ donations and this shortage translates into hundreds of thousands of lives lost annually. Traditional medicine based on the idea of “fixing” a closed system is approaching the limits of its effectiveness. At the same time, new technologies are being developed making the OSCAR concept partially feasible: 3D-bioprinting (Organovo, 3D Bioprinting Solutions), gene editing, developing biocompatible materials and neurointerfaces. However, their development is fragmented and not consolidated via a common standardized paradigm, which delays achieving the level of systemic solutions and mass markets.
“Biological Open-System Development Yard” Global Project.
What is required is not merely developing individual bioprinting technologies, but creating an international platform that would be both technological and regulatory, i.e. an operating system for modular biology. BODY-OS is an open standard (protocol) for designing, manufacturing, certifying, and integrating biocompatible modules (organs, tissues, sensory interfaces) with the purpose of making the creation and replacement of biological components not a unique surgical art, but a standardized engineering procedure with predictable outcomes.
Factual grounds:
Bioproduction: tissue engineering construction are already being printed. In 2023, Israeli scientists successfully printed and transplanted the world’s first vascularized (i.e. having blood vessels) cardiac tissue from their patient’s cells. Russia’s 3D Bioprinting Solutions printed the thyroid gland of a mouse.
Standardization in IT and engineering: the success of USB, Bluetooth, or Android proved that open-source standards accelerate innovation as they create an ecosystem of compatible component manufacturers.
Digital twins: there are international projects developing digital models of the human body (Virtual Physiological Human). BODY-OS will be their “hardware” outcome.
Operations and scaling
The platform will determine three fundamental elements of the future biomodule ecosystem. First, physical and biochemical interfaces, or standardized protocols for connecting the modules at the level of biomaterials, similar to the “magnetic connections” in OSCAR, but they will connect blood vessels, nerves, and other tissue systems.
Second, data protocols, i.e. sets of rules regulating the implanted controller (“e-brain”) as it controls the modules, and ensuring two-way data exchange both with the host’s body and with external diagnostics and monitoring systems.
Third, there will be a global register and certification system, an open database that contains information on approved modules, their compatibility with each other and with patients, and accumulates the results of clinical applications with a view to constantly improving the safety and efficiency standards.
Example:
Scenario: a Japanese company (a leader in robotics and biomaterials) develops an “artificial pancreas” high-precision module with built-in autonomous blood sugar level testing. A Swiss pharmaceutical company develops a bioengineered liver tissue with enhanced detox function.
Without BODY-OS, each of these products is a unique medical device that requires years of expensive testing in each jurisdiction. Integrating them into a single system of a patient is virtually impossible.
With BODY-OS, both modules are developed under the platform’s open standards (blood supply interfaces, connection protocols), which allows for faster joint testing and trials in several countries – parties to the initiative (such as Singapore or Germany) under mutually recognized protocols that would, down the road, use the single implanted controller (similar to OSCAR’s “e-brain”) to ensure that both devices are compatible in a patient’s body. The platform’s standards allow manufacturers from other countries (for instance, South Korea or Israel) to design competing or supplementing modules as they link to the global ecosystem, which stimulates the market and cuts prices.
Specific implementation proposals
Launching an international consortium that includes key regulators (FDA and EMA analogs), leading research centers (MIT, Skoltech, RIKEN), and technological companies. The first goal is developing a pilot standard for the module that is in the highest demand (example: an “bioartificial kidney”).
Establishing so-called “special biological economic zones” in several trailblazing states (for instance, the UAE, Singapore, Switzerland). Their territories will host adapted regulatory “sand boxes” for testing products and services under the BODY-OS standards.
Establishing a BODY-OS Grand Challenges global foundation with a prize fund for teams finding solutions to the platform’s key technological issues: devising a universal bioglue, a standardized microvascular interface, and a system for the modules’ power supply.
Major effect on educational development, i.e. introducing “open system bioengineering” programs in the leading technological and medical universities training professionals of a new kind.
Expected effects:
Economic growth, the emergence of a new global industry with a high profit margin, i.e. the “biological modules and services” market comparable to the IT sector in its size. The growth of related industries: IT (for control), advanced materials, biofabrication. Developing protocols for “biological interfaces” is the next logical step that is quite feasible given the successes of bioprinting. Investments in shaping a new global market. Current investments in bioprinting and tissue engineering are fragmented and intended to devise individual products. BODY-OS creates an infrastructure, an “ecosystem” that multiplies the value of each individual module, just like Android OS multiplied the value of millions of apps. That creates a predictable and scalable market for biomodules and services with multifold capitalization.
Implementing this model will fundamentally improve the quality of life by increasing healthy longevity, eliminating transplant waiting lists, and transitioning to personalized, predictive medicine: replacing an organ before the patient’s condition becomes critical.
Improving healthcare systems’ sustainability, reducing long-term spending on treating chronic diseases by curing them through module replacement. Shifting focus from life-long treatment to one-off “health engineering.”
Global cooperation, overcoming regulatory fragmentation, creating a common technological language will ensure that breakthrough treatments reach patients throughout the world sooner.
CONCLUSION
Concluding my essay, I would like to emphasize once again that the BODY-OS platform is a constructive response that seeks to transform ethical and technological challenges into the foundation of a new socially-oriented economy where human life is the highest value and the end product, and this life is not merely preserved, but deliberately improved thanks to a harmonious integration of the natural and the artificial. The central question is, how these breakthrough areas should be developed for economic growth and improved quality of life, and I offer the key idea as an answer: transitioning from disjointed instrument development (bioprinters, tissue engineering) to devising universal and open architecture, a global BODY-OS (Biological Open-System Development Yard) platform.
Therefore, investments in BODY-OS are not merely investments in another technology. This is strategic capital intended to create a new sector, to cut colossal social spending, to gain global technological leadership, and responsibly design the anthropological reality of the future. Those who finance the architecture today will define the outlines of the health economy and the very notion of human potential tomorrow.
REFERENCES
1. Kaayk, F. The Modular Body: An Online Science Fiction Story. (2016). URL:https://themodularbody.com/
2. Organovo Holdings, Inc.: Official website https://www.organovo.com/
3. 3D Bioprinting Solutions: official website https://bioprinting.ru/
4. Israeli scientists’ research. https://www.nbcnews.com/mach/science/israeli-scientists-create-world-s-first-3d-printed-heart-using-...
5. 3D Printing of Personalized Thick and Perfusable Cardiac Patches and Hearts. https://advanced.onlinelibrary.wiley.com/doi/full/10.1002/advs.201900344
6. Global Observatory on Donation and Transplantation (GODT) под эгидой ВОЗ: http://www.transplant-observatory.org/
7. World Health Organization (WHO). (2022). Global report on health expenditures and financing. Всемирная организация здравоохранения. https://www.who.int/
8. OECD. (2023). Health at a Glance 2023: OECD Indicators. OECD Publishing, Paris. https://www.oecd.org/en/publications/health-at-a-glance-2023_7a7afb35-en.html
9. Gawer, A., & Cusumano, M. A. (2014). Industry Platforms and Ecosystem Innovation. Journal of Product Innovation Management, 31(3), 417–433. https://onlinelibrary.wiley.com/doi/10.1111/jpim.12105
10. Tiwana, A. (2014). Platform Ecosystems: Aligning Architecture, Governance, and Strategy. Morgan Kaufmann
11. Viceconti, M., et al. (2020). Toward a regulatory framework for the virtual human. Journal of the Royal Society Interface, https://royalsocietypublishing.org/rsif/article/17/173/20200540/36089/Estimating-the-distribution-of...
12. U.S. Food and Drug Administration (FDA). (2023). Digital Health Center of Excellence. https://www.fda.gov/medical-devices/digital-health-center-excellence
13. European Medicines Agency (EMA). (2023). Innovation in medicines. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/supporting-innovation
14. World Bank. Special Economic Zones: An Operational Review of Their Impacts. https://www.worldbank.org/ext/en/development-topics
Cornelis Vlasman’s OSCAR project is hypothetical in nature, yet it is a powerful conceptual model that points to the coming technological watershed. Its central idea of transitioning from perceiving the body as a “closed system” to a “modular, open architecture” is key both to a revolution in medicine, and to shaping radically new high-tech markets and sustainable economic growth models based on the value of human life and health.
Relevance
Today, the global economy faces two challenges at once: aging population in developed countries and increasing incidence of chronic diseases, which results in massive healthcare spending. Simultaneously, there is a crisis of organ donations and this shortage translates into hundreds of thousands of lives lost annually. Traditional medicine based on the idea of “fixing” a closed system is approaching the limits of its effectiveness. At the same time, new technologies are being developed making the OSCAR concept partially feasible: 3D-bioprinting (Organovo, 3D Bioprinting Solutions), gene editing, developing biocompatible materials and neurointerfaces. However, their development is fragmented and not consolidated via a common standardized paradigm, which delays achieving the level of systemic solutions and mass markets.
“Biological Open-System Development Yard” Global Project.
What is required is not merely developing individual bioprinting technologies, but creating an international platform that would be both technological and regulatory, i.e. an operating system for modular biology. BODY-OS is an open standard (protocol) for designing, manufacturing, certifying, and integrating biocompatible modules (organs, tissues, sensory interfaces) with the purpose of making the creation and replacement of biological components not a unique surgical art, but a standardized engineering procedure with predictable outcomes.
Factual grounds:
Bioproduction: tissue engineering construction are already being printed. In 2023, Israeli scientists successfully printed and transplanted the world’s first vascularized (i.e. having blood vessels) cardiac tissue from their patient’s cells. Russia’s 3D Bioprinting Solutions printed the thyroid gland of a mouse.
Standardization in IT and engineering: the success of USB, Bluetooth, or Android proved that open-source standards accelerate innovation as they create an ecosystem of compatible component manufacturers.
Digital twins: there are international projects developing digital models of the human body (Virtual Physiological Human). BODY-OS will be their “hardware” outcome.
Operations and scaling
The platform will determine three fundamental elements of the future biomodule ecosystem. First, physical and biochemical interfaces, or standardized protocols for connecting the modules at the level of biomaterials, similar to the “magnetic connections” in OSCAR, but they will connect blood vessels, nerves, and other tissue systems.
Second, data protocols, i.e. sets of rules regulating the implanted controller (“e-brain”) as it controls the modules, and ensuring two-way data exchange both with the host’s body and with external diagnostics and monitoring systems.
Third, there will be a global register and certification system, an open database that contains information on approved modules, their compatibility with each other and with patients, and accumulates the results of clinical applications with a view to constantly improving the safety and efficiency standards.
Example:
Scenario: a Japanese company (a leader in robotics and biomaterials) develops an “artificial pancreas” high-precision module with built-in autonomous blood sugar level testing. A Swiss pharmaceutical company develops a bioengineered liver tissue with enhanced detox function.
Without BODY-OS, each of these products is a unique medical device that requires years of expensive testing in each jurisdiction. Integrating them into a single system of a patient is virtually impossible.
With BODY-OS, both modules are developed under the platform’s open standards (blood supply interfaces, connection protocols), which allows for faster joint testing and trials in several countries – parties to the initiative (such as Singapore or Germany) under mutually recognized protocols that would, down the road, use the single implanted controller (similar to OSCAR’s “e-brain”) to ensure that both devices are compatible in a patient’s body. The platform’s standards allow manufacturers from other countries (for instance, South Korea or Israel) to design competing or supplementing modules as they link to the global ecosystem, which stimulates the market and cuts prices.
Specific implementation proposals
Launching an international consortium that includes key regulators (FDA and EMA analogs), leading research centers (MIT, Skoltech, RIKEN), and technological companies. The first goal is developing a pilot standard for the module that is in the highest demand (example: an “bioartificial kidney”).
Establishing so-called “special biological economic zones” in several trailblazing states (for instance, the UAE, Singapore, Switzerland). Their territories will host adapted regulatory “sand boxes” for testing products and services under the BODY-OS standards.
Establishing a BODY-OS Grand Challenges global foundation with a prize fund for teams finding solutions to the platform’s key technological issues: devising a universal bioglue, a standardized microvascular interface, and a system for the modules’ power supply.
Major effect on educational development, i.e. introducing “open system bioengineering” programs in the leading technological and medical universities training professionals of a new kind.
Expected effects:
Economic growth, the emergence of a new global industry with a high profit margin, i.e. the “biological modules and services” market comparable to the IT sector in its size. The growth of related industries: IT (for control), advanced materials, biofabrication. Developing protocols for “biological interfaces” is the next logical step that is quite feasible given the successes of bioprinting. Investments in shaping a new global market. Current investments in bioprinting and tissue engineering are fragmented and intended to devise individual products. BODY-OS creates an infrastructure, an “ecosystem” that multiplies the value of each individual module, just like Android OS multiplied the value of millions of apps. That creates a predictable and scalable market for biomodules and services with multifold capitalization.
Implementing this model will fundamentally improve the quality of life by increasing healthy longevity, eliminating transplant waiting lists, and transitioning to personalized, predictive medicine: replacing an organ before the patient’s condition becomes critical.
Improving healthcare systems’ sustainability, reducing long-term spending on treating chronic diseases by curing them through module replacement. Shifting focus from life-long treatment to one-off “health engineering.”
Global cooperation, overcoming regulatory fragmentation, creating a common technological language will ensure that breakthrough treatments reach patients throughout the world sooner.
CONCLUSION
Concluding my essay, I would like to emphasize once again that the BODY-OS platform is a constructive response that seeks to transform ethical and technological challenges into the foundation of a new socially-oriented economy where human life is the highest value and the end product, and this life is not merely preserved, but deliberately improved thanks to a harmonious integration of the natural and the artificial. The central question is, how these breakthrough areas should be developed for economic growth and improved quality of life, and I offer the key idea as an answer: transitioning from disjointed instrument development (bioprinters, tissue engineering) to devising universal and open architecture, a global BODY-OS (Biological Open-System Development Yard) platform.
Therefore, investments in BODY-OS are not merely investments in another technology. This is strategic capital intended to create a new sector, to cut colossal social spending, to gain global technological leadership, and responsibly design the anthropological reality of the future. Those who finance the architecture today will define the outlines of the health economy and the very notion of human potential tomorrow.
REFERENCES
1. Kaayk, F. The Modular Body: An Online Science Fiction Story. (2016). URL:https://themodularbody.com/
2. Organovo Holdings, Inc.: Official website https://www.organovo.com/
3. 3D Bioprinting Solutions: official website https://bioprinting.ru/
4. Israeli scientists’ research. https://www.nbcnews.com/mach/science/israeli-scientists-create-world-s-first-3d-printed-heart-using-...
5. 3D Printing of Personalized Thick and Perfusable Cardiac Patches and Hearts. https://advanced.onlinelibrary.wiley.com/doi/full/10.1002/advs.201900344
6. Global Observatory on Donation and Transplantation (GODT) под эгидой ВОЗ: http://www.transplant-observatory.org/
7. World Health Organization (WHO). (2022). Global report on health expenditures and financing. Всемирная организация здравоохранения. https://www.who.int/
8. OECD. (2023). Health at a Glance 2023: OECD Indicators. OECD Publishing, Paris. https://www.oecd.org/en/publications/health-at-a-glance-2023_7a7afb35-en.html
9. Gawer, A., & Cusumano, M. A. (2014). Industry Platforms and Ecosystem Innovation. Journal of Product Innovation Management, 31(3), 417–433. https://onlinelibrary.wiley.com/doi/10.1111/jpim.12105
10. Tiwana, A. (2014). Platform Ecosystems: Aligning Architecture, Governance, and Strategy. Morgan Kaufmann
11. Viceconti, M., et al. (2020). Toward a regulatory framework for the virtual human. Journal of the Royal Society Interface, https://royalsocietypublishing.org/rsif/article/17/173/20200540/36089/Estimating-the-distribution-of...
12. U.S. Food and Drug Administration (FDA). (2023). Digital Health Center of Excellence. https://www.fda.gov/medical-devices/digital-health-center-excellence
13. European Medicines Agency (EMA). (2023). Innovation in medicines. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/supporting-innovation
14. World Bank. Special Economic Zones: An Operational Review of Their Impacts. https://www.worldbank.org/ext/en/development-topics
Read full text
